Akron Bio
Ezequiel Zylberberg has worked at Akron Bio since 2017. Ezequiel started as a Strategic Alliances Manager and held this role until July 2020. Ezequiel then became the VP of Product Development and Planning, a position they held until June 2023. Currently, they are the Vice President of Corporate Development at Akron Bio. Prior to their time at Akron Bio, they worked as a Research Affiliate at the Massachusetts Institute of Technology from 2014 to 2020.
Ezequiel Zylberberg began their education at the University of Florida, where they obtained a Bachelor of Arts degree in an unspecified field of study in 2009. Following this, they pursued a Master of Science degree in Development Economics at The London School of Economics and Political Science (LSE), completing it in 2011.
In 2013, Zylberberg enrolled at Saïd Business School, University of Oxford, where they spent three years pursuing a Doctor of Philosophy (PhD) degree. Unfortunately, no information about the specific field of study for their PhD is provided.
Ezequiel'seducation continued at the Massachusetts Institute of Technology (MIT), where they served as a Postdoctoral Associate between 2016 and 2017. The field of study for this position is not mentioned.
Overall, Ezequiel Zylberberg's education history reflects their engagement in various academic pursuits, including a Bachelor's degree, a Master's degree, a PhD, and a postdoctoral position at prestigious institutions.
This person is not in any offices
Akron Bio
Akron has a strategic focus on the discovery, development and manufacturing of innovative tools and technologies, and providing services for the regenerative medicine industry. As a compliant global manufacturer, Akron develops and supplies innovative solutions to key problems in the tissue engineering, cell and gene therapy industry. These includecGMP growth factors, culture media, recombinant and human proteins, novel cryopreservation media, delivery technologies and bioengineered scaffolds for discovery, development, and commercialization. Their company’s unique business model emphasizes flexibility, quality, and unparalleled service—from research and development through clinical trial, market authorization, and commercial product.